JOHANNESBURG, Jan 13 (Reuters) - South African private hospital operator Life Healthcare on Monday announced the sale of its radiopharmaceuticals business LMI to U.S.-listed Lantheus Holdings , sending its Johannesburg-listed shares higher.
Life Healthcare said it had entered into binding agreements with an entity owned by Lantheus to sell its entire stake in Life Molecular Imaging (LMI) for an upfront payment of $350 million and potential earnout payments of a further $400 million linked to future sales of LMI products up to 2034.
Radiopharmaceuticals are a new class of cancer drugs that deliver radiation therapy directly and specifically to cancer cells.
Life Healthcare shares were up by more than 3% at 1011 GMT.
The hospital operator has been selling some assets to try to reduce its operating complexity. It bought LMI in 2018 as part of its investment in the Alliance Medical Group.
"Lantheus is uniquely positioned to invest in and grow LMI's portfolio of imaging assets and ensure that the business meets its growth potential," it said in a statement on the Johannesburg Stock Exchange.
(Reporting by Sfundo Parakozov; Editing by Alexander Winning and Louise Heavens)
((Sfundo.Parakozov@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。